Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
OTCMKTS:CLPBY

Coloplast A/S (CLPBY) Stock Price, News & Analysis

Coloplast A/S logo
$6.49 +0.04 (+0.66%)
As of 12:26 PM Eastern

About Coloplast A/S Stock (OTCMKTS:CLPBY)

Advanced

Key Stats

Today's Range
$6.39
$6.59
50-Day Range
$6.13
$7.12
52-Week Range
$6.10
$10.03
Volume
174,534 shs
Average Volume
581,116 shs
Market Capitalization
$14.63 billion
P/E Ratio
46.38
Dividend Yield
5.39%
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Coloplast A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

CLPBY MarketRank™: 

Coloplast A/S scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Coloplast A/S has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Coloplast A/S has only been the subject of 1 research reports in the past 90 days.

  • Read more about Coloplast A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Coloplast A/S are expected to grow by 7.50% in the coming year, from $0.40 to $0.43 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coloplast A/S is 46.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.52.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coloplast A/S is 46.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.78.

  • Price to Earnings Growth Ratio

    Coloplast A/S has a PEG Ratio of 1.99. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Coloplast A/S has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the float of Coloplast A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Coloplast A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Coloplast A/S has recently decreased by 34.37%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    Coloplast A/S is a leading dividend payer. It pays a dividend yield of 5.59%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Coloplast A/S does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Coloplast A/S is 250.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on EPS estimates, Coloplast A/S will have a dividend payout ratio of 81.40% in the coming year. This indicates that Coloplast A/S may not be able to sustain their current dividend.

  • Read more about Coloplast A/S's dividend.
  • News Sentiment

    Coloplast A/S has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Coloplast A/S this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for CLPBY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Coloplast A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive CLPBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLPBY Stock News Headlines

Coloplast: Went 'BUY' A Bit Early
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
Coloplast appoints Gavin Wood as new CEO
Coloplast A/S - Updated Financial Calendar 2025-26
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
See More Headlines

CLPBY Stock Analysis - Frequently Asked Questions

Coloplast A/S's stock was trading at $8.50 on January 1st, 2026. Since then, CLPBY shares have decreased by 23.6% and is now trading at $6.4925.

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) released its earnings results on Tuesday, May, 12th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.11 billion. Coloplast A/S had a trailing twelve-month return on equity of 31.96% and a net margin of 7.46%.

Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/12/2026
Today
5/21/2026
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
N/A
Current Symbol
OTCMKTS:CLPBY
Previous Symbol
NASDAQ:CLPBY
CIK
1294325
Fax
N/A
Employees
17,156
Year Founded
1957

Profitability

EPS (Trailing Twelve Months)
$0.14
Trailing P/E Ratio
46.38
Forward P/E Ratio
16.23
P/E Growth
1.99
Net Income
$538.49 million
Net Margins
7.46%
Pretax Margin
22.22%
Return on Equity
31.96%
Return on Assets
10.20%

Debt

Debt-to-Equity Ratio
1.50
Current Ratio
1.30
Quick Ratio
0.81

Sales & Book Value

Annual Sales
$4.13 billion
Price / Sales
3.54
Cash Flow
$0.37 per share
Price / Cash Flow
17.54
Book Value
$1.06 per share
Price / Book
6.13

Miscellaneous

Outstanding Shares
2,253,670,000
Free Float
N/A
Market Cap
$14.63 billion
Optionable
Not Optionable
Beta
0.15

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

This page (OTCMKTS:CLPBY) was last updated on 5/21/2026 by MarketBeat.com Staff.
From Our Partners